Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Publication Type:

Journal Article

Source:

JAMA : the journal of the American Medical Association, Volume 301, Issue 22, p.2349-61 (2009)

Keywords:

2009, Antineoplastic Agents, Clinical Research Division, Clinical Trials as Topic, Humans, Leukemia, Myeloid, Acute, Public Health Sciences Division, Remission Induction, Risk Assessment, Stem Cell Transplantation, Survival Analysis, Transplantation, Homologous

Abstract:

The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML.